Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2028
This report can be delivered to the clients within 7-10 Business Days
DelveInsight’s ‘Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Renal Failure in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Renal Failure from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Acute Renal Failure - Disease Understanding and Treatment Algorithm
The DelveInsight Acute Renal Failure market report gives the thorough understanding of Acute Renal Failure by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Renal Failure in the US, Europe, and Japan.
Acute Renal Failure Epidemiology
The Acute Renal Failure epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [incidence population of ARF, Sex-Specific Incident Hospitalization cases and Stage-wise Incidence of Acute Renal Failure] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
According to DelveInsight, total incident cases of Acute Renal Failure in 7 major markets are found out to be 1,516,635 in 2016.
Acute Renal Failure Drug Chapters
This segment of the Acute Renal Failure report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are large windows of opportunity for Acute Kidney Injury (AKI): to prevent AKI, to treat AKI after its onset, and to halt progression to ESRD. The pharmaceutical industry is investing on clinical trials conducted in the cardiovascular space, yet is little reluctant to enter the kidney market as the overall market is driven by monitoring system followed by transplantation with a very small therapeutic window. Detailed chapter for upcoming therapies EA-230 (Exponential Biotherapies), Zemiglo (LG Life Sciences), RESCAP (Alloksys), BB3 (Angion Biomedica), QPI-1002 (Quark) and recAP (AM Pharma) have been covered in the report.
Acute Renal Failure Market Outlook
The Acute Renal Failure market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Acute Renal Failure in 7MM was found to be USD 8,392 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
Acute Renal Failure Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Renal Failure Report Insights
DelveInsight’s ‘Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Renal Failure in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Renal Failure from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Acute Renal Failure - Disease Understanding and Treatment Algorithm
The DelveInsight Acute Renal Failure market report gives the thorough understanding of Acute Renal Failure by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Renal Failure in the US, Europe, and Japan.
Acute Renal Failure Epidemiology
The Acute Renal Failure epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [incidence population of ARF, Sex-Specific Incident Hospitalization cases and Stage-wise Incidence of Acute Renal Failure] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
According to DelveInsight, total incident cases of Acute Renal Failure in 7 major markets are found out to be 1,516,635 in 2016.
Acute Renal Failure Drug Chapters
This segment of the Acute Renal Failure report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are large windows of opportunity for Acute Kidney Injury (AKI): to prevent AKI, to treat AKI after its onset, and to halt progression to ESRD. The pharmaceutical industry is investing on clinical trials conducted in the cardiovascular space, yet is little reluctant to enter the kidney market as the overall market is driven by monitoring system followed by transplantation with a very small therapeutic window. Detailed chapter for upcoming therapies EA-230 (Exponential Biotherapies), Zemiglo (LG Life Sciences), RESCAP (Alloksys), BB3 (Angion Biomedica), QPI-1002 (Quark) and recAP (AM Pharma) have been covered in the report.
Acute Renal Failure Market Outlook
The Acute Renal Failure market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Acute Renal Failure in 7MM was found to be USD 8,392 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
Acute Renal Failure Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Renal Failure Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Renal Failure market
- Organize sales and marketing efforts by identifying the best opportunities for Acute Renal Failure market
- To understand the future market competition in the Acute Renal Failure market.
1. KEY INSIGHTS
2. ACUTE RENAL FAILURE MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Acute Renal Failure in 2016
2.2. Market Share Distribution of Acute Renal Failure in 2028
3. DISEASE BACKGROUND AND OVERVIEW: ACUTE RENAL FAILURE (ARF)
3.1. Introduction
3.2. Symptoms
3.3. Types of Acute Renal Failure
3.4. Stages Classification
3.5. Risk Factors
3.6. Etiology
3.7. Pathophysiology
3.8. Diagnosis
3.9. Management
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Incident Cases of Acute Renal Failure in 7MM
4.4. Incident Population of Acute Renal Failure in 7MM in 2016 (%)
4.5. Incident Population of Acute Renal Failure in 7MM in 2025 (%)
5. EPIDEMIOLOGY OF ACUTE RENAL FAILURE
6. UNITED STATES
6.1. Assumptions and Rationale
6.2. Incident Population of Acute Renal Failure in the United States
6.3. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in the United States
6.4. Stage-wise Incidence of Acute Renal Failure in the United States
7. EU5
7.1. Assumptions and Rationale
7.2. Incident Population of Acute Renal Failure in Germany
7.3. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany
7.4. Stage-wise Incidence of Acute Renal Failure in Germany
7.5. France
7.5.1. Incident Populations of Acute Renal Failure in France
7.5.2. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in France
7.5.3. Stage-wise Incidence Hospitalization cases of Acute Renal Failure in France
7.6. Italy
7.6.1. Incident Hospitalization cases of Acute Renal Failure in Italy
7.6.2. Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy
7.6.3. Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy
7.7. Spain
7.7.1. Incident Hospitalization cases of Acute Renal Failure in Spain
7.7.2. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Spain
7.7.3. Stage-wise Incidence of Acute Renal Failure in Spain
7.8. United Kingdom
7.8.1. Incident hospitalization cases of Acute Renal Failure in the UK
7.8.2. Sex-Specific Incident hospitalization cases of Acute Renal Failure in the UK
7.8.3. Stage-wise Incident hospitalization cases of Acute Renal Failure in the UK
8. JAPAN
8.1. Assumptions and Rationale
8.2. Incident Hospitalization cases of Acute Renal Failure in Japan
8.3. Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan
8.4. Stage-wise Incident hospitalization cases of Acute Renal Failure in Japan
9. TREATMENT AND PREVENTION
10. GLOBAL PIPELINE PRODUCTS
11. EMERGING THERAPIES (PHASE III DRUGS)
11.1. EA-230: Exponential Biotherapies
11.1.1. Clinical Development
11.1.2. Clinical Trials Information
11.1.3. Safety and Efficacy
11.1.4. Advantages and Disadvantages
11.1.5. Product Profile
11.2. Zemiglo: LG Life Sciences
11.2.1. Clinical Development
11.2.2. Clinical Trials Information
11.2.3. Safety and Efficacy
11.2.4. Product Profile
11.3. RESCAP: Alloksys
11.3.1. Other Developmental Activities
11.3.2. Clinical Development
11.3.3. Clinical Trials Information
11.3.4. Advantages and Disadvantages
11.3.5. Product Profile
11.4. BB3: Angion Biomedica
11.5. Other Developmental Activities
11.6. Clinical Trials Information
11.7. Safety and Efficacy
11.8. Product Profile
11.9. QPI-1002: Quark
11.9.1. Other Developmental Activities
11.9.2. Clinical Development
11.9.3. Clinical Trial Information
11.9.4. Safety and Efficacy
11.9.5. Advantages and Disadvantages
11.9.6. Product Profile
11.10. recAP: AM Pharma
11.10.1. Other Developmental Activities
11.10.2. Clinical Development
11.10.3. Clinical Trial Information
11.10.4. Safety and Efficacy
11.10.5. Advantages and Disadvantages
11.10.6. Product Profile
12. 7MM MARKET SIZE OF ACUTE RENAL FAILURE
13. 7MM MARKET SHARE BY EMERGING THERAPIES
14. 7MM MARKET SHARE BY COUNTRIES
15. 7MM PATIENT SHARE BY THERAPIES
15.1. United States- Acute Renal Failure Market Size
15.1.1. US Market Share by Emerging Therapies
15.2. Germany- Acute Renal Failure Market Size
15.2.1. Germany Market Share by Emerging Therapies
15.3. France- Acute Renal Failure Market Size
15.3.1. France Market Share by Emerging Therapies
15.4. Italy- Acute Renal Failure Market Size
15.4.1. Italy Market Share by Emerging Therapies
15.5. Spain -Acute Renal Failure Market Size
15.5.1. Spain Market Share by Emerging Therapies
15.6. UK- Acute Renal Failure Market Size
15.6.1. UK Market Share by Emerging Therapies
15.7. Japan-Acute Renal Failure Market Size
15.7.1. Japan Market Share by Emerging Therapies
16. TRENDS OBSERVED IN THE COST OF THERAPIES IN ACUTE RENAL FAILURE
17. MARKET DRIVERS
18. MARKET BARRIERS
19. DELVEINSIGHT CAPABILITIES
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Sources Used
22. DISCLAIMER
23. ABOUT DELVEINSIGHT
2. ACUTE RENAL FAILURE MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Acute Renal Failure in 2016
2.2. Market Share Distribution of Acute Renal Failure in 2028
3. DISEASE BACKGROUND AND OVERVIEW: ACUTE RENAL FAILURE (ARF)
3.1. Introduction
3.2. Symptoms
3.3. Types of Acute Renal Failure
3.4. Stages Classification
3.5. Risk Factors
3.6. Etiology
3.7. Pathophysiology
3.8. Diagnosis
3.9. Management
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Incident Cases of Acute Renal Failure in 7MM
4.4. Incident Population of Acute Renal Failure in 7MM in 2016 (%)
4.5. Incident Population of Acute Renal Failure in 7MM in 2025 (%)
5. EPIDEMIOLOGY OF ACUTE RENAL FAILURE
6. UNITED STATES
6.1. Assumptions and Rationale
6.2. Incident Population of Acute Renal Failure in the United States
6.3. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in the United States
6.4. Stage-wise Incidence of Acute Renal Failure in the United States
7. EU5
7.1. Assumptions and Rationale
7.2. Incident Population of Acute Renal Failure in Germany
7.3. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany
7.4. Stage-wise Incidence of Acute Renal Failure in Germany
7.5. France
7.5.1. Incident Populations of Acute Renal Failure in France
7.5.2. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in France
7.5.3. Stage-wise Incidence Hospitalization cases of Acute Renal Failure in France
7.6. Italy
7.6.1. Incident Hospitalization cases of Acute Renal Failure in Italy
7.6.2. Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy
7.6.3. Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy
7.7. Spain
7.7.1. Incident Hospitalization cases of Acute Renal Failure in Spain
7.7.2. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Spain
7.7.3. Stage-wise Incidence of Acute Renal Failure in Spain
7.8. United Kingdom
7.8.1. Incident hospitalization cases of Acute Renal Failure in the UK
7.8.2. Sex-Specific Incident hospitalization cases of Acute Renal Failure in the UK
7.8.3. Stage-wise Incident hospitalization cases of Acute Renal Failure in the UK
8. JAPAN
8.1. Assumptions and Rationale
8.2. Incident Hospitalization cases of Acute Renal Failure in Japan
8.3. Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan
8.4. Stage-wise Incident hospitalization cases of Acute Renal Failure in Japan
9. TREATMENT AND PREVENTION
10. GLOBAL PIPELINE PRODUCTS
11. EMERGING THERAPIES (PHASE III DRUGS)
11.1. EA-230: Exponential Biotherapies
11.1.1. Clinical Development
11.1.2. Clinical Trials Information
11.1.3. Safety and Efficacy
11.1.4. Advantages and Disadvantages
11.1.5. Product Profile
11.2. Zemiglo: LG Life Sciences
11.2.1. Clinical Development
11.2.2. Clinical Trials Information
11.2.3. Safety and Efficacy
11.2.4. Product Profile
11.3. RESCAP: Alloksys
11.3.1. Other Developmental Activities
11.3.2. Clinical Development
11.3.3. Clinical Trials Information
11.3.4. Advantages and Disadvantages
11.3.5. Product Profile
11.4. BB3: Angion Biomedica
11.5. Other Developmental Activities
11.6. Clinical Trials Information
11.7. Safety and Efficacy
11.8. Product Profile
11.9. QPI-1002: Quark
11.9.1. Other Developmental Activities
11.9.2. Clinical Development
11.9.3. Clinical Trial Information
11.9.4. Safety and Efficacy
11.9.5. Advantages and Disadvantages
11.9.6. Product Profile
11.10. recAP: AM Pharma
11.10.1. Other Developmental Activities
11.10.2. Clinical Development
11.10.3. Clinical Trial Information
11.10.4. Safety and Efficacy
11.10.5. Advantages and Disadvantages
11.10.6. Product Profile
12. 7MM MARKET SIZE OF ACUTE RENAL FAILURE
13. 7MM MARKET SHARE BY EMERGING THERAPIES
14. 7MM MARKET SHARE BY COUNTRIES
15. 7MM PATIENT SHARE BY THERAPIES
15.1. United States- Acute Renal Failure Market Size
15.1.1. US Market Share by Emerging Therapies
15.2. Germany- Acute Renal Failure Market Size
15.2.1. Germany Market Share by Emerging Therapies
15.3. France- Acute Renal Failure Market Size
15.3.1. France Market Share by Emerging Therapies
15.4. Italy- Acute Renal Failure Market Size
15.4.1. Italy Market Share by Emerging Therapies
15.5. Spain -Acute Renal Failure Market Size
15.5.1. Spain Market Share by Emerging Therapies
15.6. UK- Acute Renal Failure Market Size
15.6.1. UK Market Share by Emerging Therapies
15.7. Japan-Acute Renal Failure Market Size
15.7.1. Japan Market Share by Emerging Therapies
16. TRENDS OBSERVED IN THE COST OF THERAPIES IN ACUTE RENAL FAILURE
17. MARKET DRIVERS
18. MARKET BARRIERS
19. DELVEINSIGHT CAPABILITIES
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Sources Used
22. DISCLAIMER
23. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Total Incident Population of Acute Renal Failure in 7 MM (2016-2028)
Table 2: Incident Population of Acute Renal Failure in the United States (2016-2028)
Table 3: Sex-Specific Incident Hospitalization of Acute Renal Failure in the United States (2016-2028)
Table 4: Stage-wise Population of Acute Renal Failure in the United States (2016-2028)
Table 5: Incident Population of Acute Renal Failure in Germany (2016-2028)
Table 6: Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany (2016-2028)
Table 7: Stage-wise Incidence Population of Acute Renal Failure in Germany (2016-2028)
Table 8: Incident Population of Acute Renal Failure in France (2016-2028)
Table 9: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Table 10: Stage-wise incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Table 11: Incident Population of Acute Renal Failure in Italy (2016-2028)
Table 12: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Table 13: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Table 14: Incident Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
Table 15: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
Table 16: Stage-wise Incident cases of Acute Renal Failure in Spain (2016-2028)
Table 17: Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
Table 18: Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
Table 19: Stage-wise Incident hospitalization of Acute Renal Failure in the United Kingdom (2016-2028)
Table 20: Incident Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Table 21: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Table 22: Stage wise Incident hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Table 23: EA-230, Description, 2016
Table 24: Zemiglo, Clinical Trial Description, 2016
Table 25: bRESCAP, Clinical Trial Description, 2016
Table 26: BB3, Clinical Trial Description, 2016
Table 27: QPI-1002, Clinical Trial Description, 2016
Table 28: recAP, Clinical Trial Description, 2016
Table 29: 7MM Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
Table 30: 7MM Acute Renal Failure Sales by Therapies (2021-2027)
Table 31: MM Market Share of Acute Renal Failure by countries, (2016 & 2027)
Table 32: Global Patient Share by Therapies (2016 & 2025)
Table 33: US Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 34: US Acute Renal Failure Sales by Therapies (2021-2027)
Table 35: Germany Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 36: Germany Acute Renal Failure Sales by Therapies (2021-2027)
Table 37: France Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 38: France Acute Renal Failure Sales by Therapies (2021-2027)
Table 39: Italy Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 40: Italy Acute Renal Failure Sales by Therapies (2021-2027)
Table 41: Spain Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 42: Spain Acute Renal Failure Sales by Therapies (2021-2027)
Table 43: UK Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 44: UK Acute Renal Failure Sales by Therapies (2021-2027)
Table 45: Japan Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 46: Japan Acute Renal Failure Sales by Therapies (2021-2027)
Table 1: Total Incident Population of Acute Renal Failure in 7 MM (2016-2028)
Table 2: Incident Population of Acute Renal Failure in the United States (2016-2028)
Table 3: Sex-Specific Incident Hospitalization of Acute Renal Failure in the United States (2016-2028)
Table 4: Stage-wise Population of Acute Renal Failure in the United States (2016-2028)
Table 5: Incident Population of Acute Renal Failure in Germany (2016-2028)
Table 6: Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany (2016-2028)
Table 7: Stage-wise Incidence Population of Acute Renal Failure in Germany (2016-2028)
Table 8: Incident Population of Acute Renal Failure in France (2016-2028)
Table 9: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Table 10: Stage-wise incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Table 11: Incident Population of Acute Renal Failure in Italy (2016-2028)
Table 12: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Table 13: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Table 14: Incident Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
Table 15: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
Table 16: Stage-wise Incident cases of Acute Renal Failure in Spain (2016-2028)
Table 17: Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
Table 18: Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
Table 19: Stage-wise Incident hospitalization of Acute Renal Failure in the United Kingdom (2016-2028)
Table 20: Incident Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Table 21: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Table 22: Stage wise Incident hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Table 23: EA-230, Description, 2016
Table 24: Zemiglo, Clinical Trial Description, 2016
Table 25: bRESCAP, Clinical Trial Description, 2016
Table 26: BB3, Clinical Trial Description, 2016
Table 27: QPI-1002, Clinical Trial Description, 2016
Table 28: recAP, Clinical Trial Description, 2016
Table 29: 7MM Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
Table 30: 7MM Acute Renal Failure Sales by Therapies (2021-2027)
Table 31: MM Market Share of Acute Renal Failure by countries, (2016 & 2027)
Table 32: Global Patient Share by Therapies (2016 & 2025)
Table 33: US Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 34: US Acute Renal Failure Sales by Therapies (2021-2027)
Table 35: Germany Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 36: Germany Acute Renal Failure Sales by Therapies (2021-2027)
Table 37: France Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 38: France Acute Renal Failure Sales by Therapies (2021-2027)
Table 39: Italy Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 40: Italy Acute Renal Failure Sales by Therapies (2021-2027)
Table 41: Spain Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 42: Spain Acute Renal Failure Sales by Therapies (2021-2027)
Table 43: UK Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 44: UK Acute Renal Failure Sales by Therapies (2021-2027)
Table 45: Japan Market Size of Acute Renal Failure in USD, Million (2016-2028)
Table 46: Japan Acute Renal Failure Sales by Therapies (2021-2027)
LIST OF FIGURES
Figure 1: Types of Acute Renal Failure
Figure 2: Risk factors associated with Acute Kidney Failure
Figure 3: Pathophysiology of AKI
Figure 4: Biomarkers of AKI
Figure 5: Total Incident Population of Acute Renal Failure in 7 MM (2016-2028)
Figure 6: Incident Population of Acute Renal Failure in the United States (2016-2028)
Figure 7: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in the United States (2016-2028)
Figure 8: Stage-wise Incident Population of Acute Renal Failure in the United States (2016-2028)
Figure 9: Incident Population of Acute Renal Failure in Germany (2016-2028)
Figure 10: Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany (2016-2028)
Figure 11: Stage-wise Incidence Population of Acute Renal Failure in Germany (2016-2028)
Figure 12: Incident Population of Acute Renal Failure in France (2016-2028)
Figure 13: Sex- Specific Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Figure 14: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Figure 15: Incident Population of Acute Renal Failure in Italy (2016-2028)
Figure 16: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Figure 17: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Figure 18: Incident Population of Acute Renal Failure in Spain (2016-2028)
Figure 19: Sex- Specific Incidence Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
Figure 20: Stage wise Incidence of Acute Renal Failure in Spain (2016-2028)
Figure 21: Incident Population of Acute Renal Failure in the United Kingdom (2016-2028)
Figure 22: Sex-Specific Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
Figure 23: Stage wise Incident hospitalization of Acute Renal Failure in the United Kingdom (2016-2028)
Figure 24: Incident Population of Acute Renal Failure in Japan (2016-2028)
Figure 25: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Figure 26: Stage wise Incident hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Figure 27: Global Mortality of ARF
Figure 28: 7MM Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
Figure 29: 7MM Acute Renal Failure Sales by Therapies (2021-2027)
Figure 30: 7MM Market Share of Acute Renal Failure by countries (2016 & 2027)
Figure 31: Global Patient Share by Therapies (2016 & 2025)
Figure 32: US Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 33: US Acute Renal Failure Sales by Therapies (2021-2027)
Figure 34: Germany Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 35: Germany Acute Renal Failure Sales by Therapies (2021-2027)
Figure 36: France Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 37: France Acute Renal Failure Sales by Therapies (2021-2027)
Figure 38: Italy Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 39: Italy Acute Renal Failure Sales by Therapies (2021-2027)
Figure 40: Spain Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 41: Spain Acute Renal Failure Sales by Therapies (2021-2027)
Figure 42: UK Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 43: UK Acute Renal Failure Sales by Therapies (2021-2027)
Figure 44: Japan Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
Figure 45: Japan Acute Renal Failure Sales by Therapies (2021-2027)
Figure 46: Market Drivers
Figure 47: Market Barriers
Figure 1: Types of Acute Renal Failure
Figure 2: Risk factors associated with Acute Kidney Failure
Figure 3: Pathophysiology of AKI
Figure 4: Biomarkers of AKI
Figure 5: Total Incident Population of Acute Renal Failure in 7 MM (2016-2028)
Figure 6: Incident Population of Acute Renal Failure in the United States (2016-2028)
Figure 7: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in the United States (2016-2028)
Figure 8: Stage-wise Incident Population of Acute Renal Failure in the United States (2016-2028)
Figure 9: Incident Population of Acute Renal Failure in Germany (2016-2028)
Figure 10: Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany (2016-2028)
Figure 11: Stage-wise Incidence Population of Acute Renal Failure in Germany (2016-2028)
Figure 12: Incident Population of Acute Renal Failure in France (2016-2028)
Figure 13: Sex- Specific Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Figure 14: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
Figure 15: Incident Population of Acute Renal Failure in Italy (2016-2028)
Figure 16: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Figure 17: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
Figure 18: Incident Population of Acute Renal Failure in Spain (2016-2028)
Figure 19: Sex- Specific Incidence Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
Figure 20: Stage wise Incidence of Acute Renal Failure in Spain (2016-2028)
Figure 21: Incident Population of Acute Renal Failure in the United Kingdom (2016-2028)
Figure 22: Sex-Specific Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
Figure 23: Stage wise Incident hospitalization of Acute Renal Failure in the United Kingdom (2016-2028)
Figure 24: Incident Population of Acute Renal Failure in Japan (2016-2028)
Figure 25: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Figure 26: Stage wise Incident hospitalization cases of Acute Renal Failure in Japan (2016-2028)
Figure 27: Global Mortality of ARF
Figure 28: 7MM Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
Figure 29: 7MM Acute Renal Failure Sales by Therapies (2021-2027)
Figure 30: 7MM Market Share of Acute Renal Failure by countries (2016 & 2027)
Figure 31: Global Patient Share by Therapies (2016 & 2025)
Figure 32: US Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 33: US Acute Renal Failure Sales by Therapies (2021-2027)
Figure 34: Germany Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 35: Germany Acute Renal Failure Sales by Therapies (2021-2027)
Figure 36: France Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 37: France Acute Renal Failure Sales by Therapies (2021-2027)
Figure 38: Italy Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 39: Italy Acute Renal Failure Sales by Therapies (2021-2027)
Figure 40: Spain Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 41: Spain Acute Renal Failure Sales by Therapies (2021-2027)
Figure 42: UK Market Size of Acute Renal Failure in USD, Million (2016-2028)
Figure 43: UK Acute Renal Failure Sales by Therapies (2021-2027)
Figure 44: Japan Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
Figure 45: Japan Acute Renal Failure Sales by Therapies (2021-2027)
Figure 46: Market Drivers
Figure 47: Market Barriers
